Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group

Marine Sroussi 1 Reza Elaidi Aude Fléchon 2 Marianne Lorcet 2 Delphine Borchiellini 3 Magalie Tardy 3 Gwenaelle Gravis 4 Mathilde Guérin 5 Brigitte Laguerre 6 Florian Estrade 6 Rémi Delva 7 Phillipe Barthélémy 8 Yohann Loriot 9, 10 Pernelle Lavaud 10 Thierry Lebret 11 Yann Neuzillet 11 Nicolas Penel 12 Nadine Houédé 13, 14 Damien Pouessel 15 Benoit Rousseau 16 Elodie Mussat 16 Marine Gross-Goupil 17 Stéphane Culine 18 Hélène Gauthier 18 Aurélien Gobert 19 Morgan Rouprêt 20 Olivier Huillard 21 Sophie Tartas 22 Camélia Radulescu 11 Yves Allory 11 Stéphane Oudard 1
Abstract : BACKGROUND: Neuroendocrine carcinoma of the urinary bladder (NCUB) is rare, accounting for < 1% of bladder cancer cases, with scarce reported data available. MATERIALS AND METHODS: We retrospectively reviewed the data from patients with NCUB treated at French institutions. The objectives were to describe the patient characteristics, treatments received, and outcomes (ie, disease-free survival [DFS], progression-free survival, overall survival [OS]) and investigate the prognostic factors. RESULTS: From 1997 to 2017, we included 236 patients, 173 with early-stage NCUB and 63 with advanced-stage NCUB. For those with early-stage disease, the median DFS was better for the patients who had received cisplatin-based chemotherapy compared with carboplatin (hazard ratio [HR], 1.95; 95% confidence interval [CI], 1.1-3.46), with no difference found between the neoadjuvant and adjuvant settings (HR, 1.1; 95% CI, 0.61-1.97). The median OS was 36 months (95% CI, 29-43 months) for stage I and II, 26 months (95% CI, 18 months to not reached) for stage IIIA, 16 months (95% CI, 12-21 months) for stage IIIB. The HR for stage IIIB compared with stage I/II was 2.6 (95% CI, 1.5-4.4). The DFS at 6 months was associated with OS (HR, 7.8; 95% CI, 4.1-15.0). For patients with metastases at diagnosis who had received chemotherapy, the median progression-free survival was 9 months (95% CI, 8-11) for first-line cisplatin and 6 months (95% CI, 4-13 months) for carboplatin; the median OS was 13 months (95% CI, 9-15 months). A high-risk Bajorin score (HR, 11.5; 95% CI, 1.2-112.6) and the use of carboplatin (HR, 2.26; 95% CI, 1.03-4.96) were associated with worse outcomes. CONCLUSIONS: In early-stage disease, a shorter DFS was associated with worse OS, and the use of cisplatin was associated with better OS. For the patients with metastases at diagnosis, a high-risk Bajorin score and the use of carboplatin were associated with worse outcomes.
Liste complète des métadonnées
Contributeur : Mélanie Karli <>
Soumis le : mardi 28 avril 2020 - 11:13:27
Dernière modification le : mercredi 29 avril 2020 - 01:46:14



Marine Sroussi, Reza Elaidi, Aude Fléchon, Marianne Lorcet, Delphine Borchiellini, et al.. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clinical Genitourinary Cancer, Elsevier, 2019, ⟨10.1016/j.clgc.2019.11.014⟩. ⟨hal-02556645⟩



Consultations de la notice